This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
million by 2030, a CAGR of 31.3 per cent (2025-2030), driven by the anticipated launch of two high-priced targeted therapies for FXS in 2027, according to GlobalData. There are currently no approved therapies available for FXS; prescribed treatment consists exclusively of off-label drugs that target individual symptoms of the disease.
By 2030, half of all US adults are predicted to be obese (New England Journal of Medicine). The company’s Phase III product Rybelsus, already FDA approved for cardiovascular risk factors and type 2 diabetes, is being positioned for a label expansion to include obesity.
billion in sales by 2030, according to GlobalData. billion by 2030, far outshining Xofigo. billion by 2030. Despite its forecasted sales performance paling in comparison to Pluvicto by 2030, the use of alpha-emitting actinium-225 could prove to be the future of RLTs in this therapeutic landscape.
In addition, the nutra market boom in APAC that began during the COVID-19 pandemic continues to accelerate looking for green-label, plant-based capsules for encapsulation. We also see a growing emphasis on sustainable practices in manufacturing and packaging, aligning with global trends in reducing carbon footprint and waste.
The endometriosis market is expected to grow from $1.05bn in 2020 to $2.72bn in 2030 at a compound annual growth rate (CAGR) of 10.0% The figure below summarises the endometriosis market growth across the 7MM from 2020 to 2030. At the end of 2030, the US will contribute approximately 81.3% of 7MM sales.
Despite this setback, the CRL being issued was not because of inadequacies or concerns regarding lebrikizumab’s Phase III efficacy and safety data that supported the BLA to the FDA or concerns with the proposed US label of the product. billion across the 7MM for AD in 2030.
Yescarta for blood cancer Yescarta is targeting expansions into the first line for diffuse large B-cell lymphoma (DLBCL) and second line for follicular lymphoma in 2030. It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7
billion by 2030, according to a GlobeNewsWire report. “With increased pharma involvement in the nutraceutical domain, this will help streamline process compliance, raise product quality standards, and provide safety labeling, which will enhance consumer awareness and acceptance, ultimately fueling sector growth,” he adds.
The Indian pharma industry is on a solid growth trajectory, surging from $40 billion in 2021 to an estimated $130 billion in 2030, with a steady double-digit CAGR for the next 10 years. In addition to meeting strong domestic demand, the Indian pharmaceutical industry is well poised as a robust contributor to the growing global market.
per cent between 2020 and 2030. Many of these therapies are used off label. Filippos Maniatis, Healthcare Analyst at GlobalData, states, “It is an exciting time for the treatment landscape of AD as multiple therapies are coming closer to approval. Vtama and Zoryve possess interesting mechanisms of action (MoAs).
Adopting the Intel Inside strategy, OmniActive’s bid to avoid commoditisation includes getting mentioned as a branded nutra ingredient on global labels. He also spells out what policy support is needed from government to ensure India’s nutra sector reaches USD 100 billion by 2030.
billion by 2030, subject to approval, and the competition in the bronchiectasis treatment landscape is expected to increase over the next few years. According to GlobalData’s Sales and Forecast database, brensocatib’s sales are anticipated to reach $1.2
.” A recent report from Clarivate highlighted ritlecitinib as one of 14 potential blockbusters to watch this year, pointing to its rapid onset of action and expected label for both adults and adolescents – Olumiant is so far only approved for use in adults. The report predicts that the alopecia areata market will grow to as much as $2.5
billion in 2023 for its obesity and diabetes blockbuster drugs Ozempic (off-label for obesity) and Wegovy respectively, facilitated the growth. Mounjaro, Zepbound, and Ozempic are expected to surpass Merck & Co’s Keytruda in global analyst consensus sales by 2030″ This is despite an “overall 1.6 Global sales of $13.9
We look forward to pivotal studies that will enable VOLT01 to have a label for pain relief of osteoarthritis in all joints along with disease modification after a single yearly infusion.” “More importantly, VOLT01 showed disease modifying activity as measured by MRI with pain relief correlating with disease modification. “We
We look forward to pivotal studies that will enable VOLT01 to have a label for pain relief of osteoarthritis in all joints along with disease modification after a single yearly infusion.” “More importantly, VOLT01 showed disease modifying activity as measured by MRI with pain relief correlating with disease modification. “We
The FDA has approved expanded labelling for Abbott’s CardioMEMS HF System, an implantable sensor that provides an early warning of worsening heart failure, that could make it an option for more than a million more patients. More than 6.2
By 2030, it is estimated there will be only 4 potential family caregivers per older adult and some are also caring for children of their own. Pharma can help with caregiver-relevant labeling, training to perform nursing duties, and a multitude of other support services.
billion in 2024 to over 32 billion in 2030. By engaging in roundtable discussions, drafting stimuli articles, and developing work plans with HQS Expert Committees, USP is setting high-quality standards, covering aspects such as labeling, version control, classification, health equity, and accessibility.
He is giving Trodelvy a 40% chance of approval and launch with a third-line label in HR+/HER2- breast cancer in 2024, with $900 million in potential sales from the indication, if TROPiCS-02 is positive at the final readout. The company said it “remains confident in that goal.” appeared first on.
market by 2030, and this growth is not limited to the U.S., In the meantime, USP encourages interested parties to reach out for more information as USP approaches its new 2025-2030 cycle. The DTx landscape is evolving rapidly, with more than 40 prescription digital therapeutics already available in the U.S. in the U.S.
This, in turn, has opened a huge opportunity for the nutraceuticals industry globally and India is uniquely positioned to become one of the most formidable players in this segment, with a projected $100 billion valued market by 2030. Read: [link] www.expresspharma.in/six-reasons-why-india-is-poised-to-be-aglobal-leader-in-nutraceuticals/
It is estimated that the global people analytics market is set grow five-fold to over US$10 billion by 2030, driven by its increasing adoption, While there are several implementation success stories, many organizations still struggle to derive optimum value. These biases can creep into AI models and their recommendations.
2001;161(16):2030-6. vs 10.3% • p < 0.05, NNT = 5 Gerardo CJ, 2017 RCT in 18 ED in the US (n = 74) Crofab ® versus placebo to measure limb function 14 days after envenomation using Patient-Specific Functional Scale Crofab reduced limb disability measured by the Patient-Specific Functional Scale 14 days after copperhead envenomation. •
Several US KOLs have acknowledged that they utilise Nuzyra off-label for the treatment of NTM-PD caused by the species Mycobacterium abscessus and M. According to GlobalData estimates, Nuzyra for the treatment of NTM-PD is expected to launch in the US in 2029 and in the EU in 2030. avium complex (MAC).
In addition, Mounjaro is estimated to gain sales of around $20bn by 2030 and become the leading GLP-1 in the obesity market, as well as in T2D. Mounjaro’s approval in 2022 for T2D has already led to many prescribers providing the therapy off-label to their patients to help them lose weight.
Most of the drugs currently used to treat NTM infections are used off-label, which leaves a critical unmet need for new therapeutic options with improved efficacy, specifically approved for the use of NTM infections.” Several US KOLs have acknowledged that they utilise omadacycline off-label for the treatment of NTM-PD caused by MABc and M.
The antibody-based drug has been cleared by the European Commission with a broad label, covering both full-term and pre-term babies and those with a range of health conditions that could make the vulnerable to RSV, said the two pharma groups in a statement. It is the first approval for Beyfortus (nirsevimab) by any regulatory authority.
With 90% of adolescents that should be vaccinated by 2030, Luppi deems it an opportunity. Everyone has a mobile: now is the age of electronic patient information; now is the time for electronic labelling. Nonetheless, with regards to research, we are living in a renaissance age, she argued, in terms of prevention, as much as treatment.
Between 2016 and 2019, DNDi and its partners led an open-label, Phase II/III study to assess the safety and efficacy of acoziborole in patients with early- and late-stage g-HAT. In alignment with the World Health Organization (WHO) Neglected Tropical Diseases Roadmap strategy, which aims to eliminate sleeping sickness by 2030.
of revenue in 2023 from its four in-line therapies & bringing Pfizer $10B+ in risk-adjusted revenues by 2030. 4 approved medicines across solid tumors & hematologic malignancies, incl. 3 ADCs: Adcetris, Padcev & Tivdak.
Achieved a 50 per cent decrease in landfill waste from a 2019 baseline, reaching the 2025 goal early and setting Waters on track for zero waste to landfills by 2030. Reduced water use intensity in business operations by 29 per cent from a 2019 baseline through infrastructure and manufacturing improvements across global facilities.
per cent expected from 2025 to 2030, the event will serve as a hub for Distributors, Procurement Managers, Product Development Experts, Regulatory Affairs Professionals, and R&D specialists. As the industry continues to grow, prioritising product quality, safety, and accurate labelling has become essential. In India, a nation of 1.4
Digital innovation is a critical piece of the response to this challenge, and as part of our ongoing commitment to the environment, AstraZeneca has begun the transition to electronic product information (ePI) , with the goal of introducing ePI across all products by 2030.
By 2030, JCAs will be carried out on all medicinal products with an EMA-issued MA. However, he did point out that the joint assessment could be a useful way of narrowing down typically broad EMA label content to specific patient populations. As part of the decision-making process, they may request further evidence.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content